

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE

03 FEB 14

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name			
GlaxoSmithKline			
2. Address <input type="checkbox"/> Check if different than previously reported			
1500 K Street, NW Suite 650			
3. Principal Place of Business (if different from line 2)			
City: Washington, DC		State/Zip (or Country) 20005	
4. Contact Name	Telephone	E-mail (optional)	5. Senate ID#
Janie A. Kinney	202-715-1000		16293-12
7. Client Name	<input checked="" type="checkbox"/> Self		6. House ID#
			31461000

TYPE OF REPORT 8. Year 2002 Midyear (January 1-June 30) Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇒ Termination Date _____ 11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organization
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Expenses (nearest \$20,000)	\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>2,500,000</u> Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of
	<input checked="" type="checkbox"/> Method A. Reporting amounts used LDA de
	<input type="checkbox"/> Method B. Reporting amounts under section of the Internal Revenue Code
	<input type="checkbox"/> Method C. Reporting amounts under section Internal Revenue Code

Signature



Date

February 14 2003

Signature [Handwritten Signature] Date February 21, 2008

Printed Name and Title Janie A. Kinney , Vice President, Federal Government Relations & Public Policy

LD-2 (REV. 6/98)

Page

Registrant Name GlaxoSmithKline Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each c** information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

- S. 754 The Drug Competition Act of 2001
- S. 812 Greater Access to Affordable Pharmaceuticals Act
- H.R. 1862 Greater Access to Affordable Pharmaceuticals Act
- H.R. 741 Madrid Protocol Implementation


17. House(s) of congress and Federal agencies contacted Check if None

U.S. House Of Representatives
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Janie A. Kinney	
Sarah J. Walsh	
Patrick McLain	
William Schuyler	
Elizabeth York	
Kimberly A. Williams	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date February 14, 2003

Printed Name and Title

Janie A. Kinney , Vice President, Federal Government Relations & Public Policy

LD-2 (REV. 6/98)

Page

Registrant Name GlaxoSmithKline Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each c** information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

S. 358 Medicare Prescription Drug & Modernization Act of 2001
 H.R. 1400 Prescription Drug Fairness for Seniors Act of 2001
 H.R. 1229 Medicare, Medicaid and MCH Smoking Cessation Promotion Act
 S. 854 Medicare, Medicaid and MCH Smoking Cessation Promotion Act

17. House(s) of congress and Federal agencies contacted Check if None

U. S. House
 U. S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Janie A. Kinney	
Sarah J. Walsh	
Patrick McLain	
William Schuyler	
Elizabeth York	
Kimberly A. Williams	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature

Janie A. Kinney

Date

February 14, 2003

Printed Name and Title

Janie A. Kinney , Vice President, Federal Government Relations & Public Policy

LD-2 (REV. 6/98)

Page

Registrant Name GlaxoSmithKline Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each** information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

S. 1764 Biological and Chemical Weapons Research Act
 H.R. 3448 Public Health Security and Bioterrorism Response Act of 2001
 H.R. 2116 Supplemental Appropriations Act
 H.R. 1504 Vaccines for the New Millenium Act
 S. 895 Vaccines for the New Millenium Act
 H.R. 580 Comprehensive Insurance Coverage of Childhood Immunization
 H.R. 2063 Early Treatment for HIV Act
 S. 987 Early Treatment for HIV Act
 HR 5605 Dept of Veterns Affairs Appropriations Act
 H.R. 4553 Amend Internal Revenue Code of 1986 to provide that the vaccine tax shall apply to any vaccine ag
 Hepatitis A

17. House(s) of congress and Federal agencies contacted Check if None

U.S. House of Representatives
 U.S. Senate
 Office of Management & Budget
 HHS

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Janie A. Kinney	
Sarah J. Walsh	
Patrick McLain	
William Schuyler	
Elizabeth York	
Kimberly A. Williams	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature

Wassiliou
 Filing #01f790d1-b12a-4c35-88be-3376665cf49c - Page 7 of 14

Date

February 14 2003

Signature

Janie A. Kinney

Printed Name and Title

Janie A. Kinney, Vice President, Federal Government Relations & Public Policy

LD-2 (REV. 6/98)

Page

Registrant Name GlaxoSmithKline Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each** information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

H.R. 1287 Amend the Public Health Service Act with respect to the Vaccine Injury Compensation Program
 H.R. 2701 Amend title XIX of the Social Security Act
 H.R. 3741 National Vaccine Injury Compensation Program Improvement Act of 2002
 H.R. 5005 Homeland Security Act of 2002
 H.R. 5282 Improved Vaccine Affordability and Availability Act
 S. 2053 Improved Vaccine Affordability and Availability Act
 S. 2049 Childhood Vaccine Supply Act of 2002
 S. 573 Amend Title XIX of the Social Security Act

17. House(s) of congress and Federal agencies contacted Check if None

U.S. House of Representatives
 U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Janie A. Kinney	
Sarah J. Walsh	
Patrick McLain	
William Schuyler	
Elizabeth York	
Kimberly A. Williams	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature *Janie A. Kinney* Date February 14, 2003

Registrant Name GlaxoSmithKline Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each** information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

S. 838 The Best Pharmaceuticals for Children Act
 S. 2330 Agriculture Appropriations Act of 2002
 S. 1731 Puppy Protection Act
 H. Con. Res. 197 Chronic Obstructive Pulmonary Disease Awareness Month
 H.R. 2887 Best Pharmaceuticals for Children Act

17. House(s) of congress and Federal agencies contacted Check if None

U. S. House of Representatives
 U. S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Janie A. Kinney	
Sarah J. Walsh	
Patrick McLain	
William Schuyler	
Elizabeth York	
Kimberly A. Williams	
Mary Frances Daly	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature

Janie A. Kinney

Date

February 14, 2003

Printed Name and Title

Janie A. Kinney, Vice President, Federal Government Relations & Public Policy

LD-2 (REV. 6/98)

Page

Registrant Name GlaxoSmithKline Client Name Self

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different from line 20)

City _____ State/Zip (or Country) _____

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that **no longer** pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of (city and state or

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities
NONE			

28. Name of each previously reported foreign entity that **no longer** owns, **or** controls, **or** is affiliated with the registrant, client or affiliated organization

Signature



Date

February 14, 2003

Printed Name and Title

Janie A. Kinney, Vice President, Federal Government Relations & Public Policy

LD-2 (REV. 6/98)

Page 7 of 7